Mar. 18 at 8:12 PM
eXoZymes (Nasdaq:
$EXOZ) has announced a third-party validation milestone for its cell-free biomanufacturing platform: independent partner Cayman Chemical successfully ran eXoZymes’ technology at pilot scale, delivering results consistent with, and in some cases exceeding, earlier internal runs.
eXoZymes is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1.
Using eXoZymes’ tech transfer package, Cayman Chemical scaled the process from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. Despite encountering real-world conditions such as pH variation and precipitation, factors that often cause enzyme-based processes to fail, the reaction performed reliably throughout, producing more than 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity and achieving 99% conversion of feedstock to end product.
Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical, commented: “During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!”
eXoZymes CCO Damien Perriman added: “This pilot run is an important validation of our cell-free platform, demonstrating that it performs reliably at scale and delivers strong results in the hands of an external partner. The fact that this project reached pilot scale in less than a year underscores our ability to move R&D at a disruptive pace - and just as importantly - it meaningfully reduces platform execution risk by showing that our technology can be transferred and operated successfully beyond our own labs. With more than 500 grams of pharma-grade NCT now available from this run, we are actively engaging partners interested in evaluation, formulation development, and potential commercialization.”
Read the full press release here: https://exozymes.com/blog/cayman-validation
eXoZymes is a Monrovia, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals.
eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff.
To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor.
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
